Adial Pharmaceuticals Inc (ADIL)
US Market

Adial Pharmaceuticals (ADIL) Stock Price & Analysis


ADIL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.20 - $2.27
Previous Close$0.42
Average Volume (3M)779.71K
Market Cap
Enterprise Value$6.30M
Total Cash (Recent Filing)$5.75M
Total Debt (Recent Filing)$220.25K
Price to Earnings (P/E)-0.6
Nov 14, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding26,853,962
10 Day Avg. Volume141,926
30 Day Avg. Volume779,708
Standard Deviation0.33
Financial Highlights & Ratios
Price to Book (P/B)2.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.44
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Adial Pharmaceuticals Inc’s price range in the past 12 months?
Adial Pharmaceuticals Inc lowest stock price was $0.20 and its highest was $2.27 in the past 12 months.
    What is Adial Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is Adial Pharmaceuticals Inc’s upcoming earnings report date?
    Adial Pharmaceuticals Inc’s upcoming earnings report date is Nov 14, 2022 which is 128 days ago.
      How were Adial Pharmaceuticals Inc’s earnings last quarter?
      Adial Pharmaceuticals Inc released its earnings results on May 16, 2022. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.04.
        Is Adial Pharmaceuticals Inc overvalued?
        According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Adial Pharmaceuticals Inc pay dividends?
          Adial Pharmaceuticals Inc does not currently pay dividends.
          What is Adial Pharmaceuticals Inc’s EPS estimate?
          Adial Pharmaceuticals Inc’s EPS estimate is -$0.18.
            How many shares outstanding does Adial Pharmaceuticals Inc have?
            Adial Pharmaceuticals Inc has 28,516,563 shares outstanding.
              What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?
              Adial Pharmaceuticals Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?
                Currently, no hedge funds are holding shares in ADIL


                Adial Pharmaceuticals Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Adial Pharmaceuticals Inc

                Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Can B
                Artelo Biosciences
                Barrel Energy
                Dermata Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis